HDAC
Histone deacetylases (HDACs), known for their ability to target histones as well as more than 50 non-histone proteins, are classified into three major classes according to their homology to yeast proteins, including class I (HDAC1, HDAC2, HDAC3 and HDAC8), class II (HDAC4, HDAC5, HDAC7 and HDAC9) and class IV (HDAC11). HDAC inhibitors, a large group of compounds that is able to induce the accumulation of acetylated histones as well as non-histone proteins, are divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids and benzamides. HDAC inhibitors have been investigated for their efficacy as anticancer agents in the treatment of a wild range of cancers.
- B3704 Nexturastat ATarget: Histone Deacetylases (HDACs)Summary: HDAC6 inhibitor,highly potent and selective
- B4106 4SC-202Summary: Class I HDAC inhibitor
- B4655 BMS-345541(free base)Summary: IKK-1/IKK-2 inhibitor,potent and selective
- A3755 Resminostat hydrochlorideSummary: HDAC inhibitor
- A3761 RG2833Target: HDACSummary: Brain-penetrant HDAC inhibitor
- A3860 TasquinimodSummary: Antiangiogenic and antineoplastic agent
- A4493 KD 51701 CitationSummary: HDAC inhibitor
- A4495 NCH 51Summary: Histone deacetylase (HDAC) inhibitor
- A4496 NSC 3852Target: Histone Deacetylases (HDACs)Summary: HDAC inhibitor
- A4497 PyroxamideTarget: Histone Deacetylases (HDACs)Summary: HDAC1 inhibitor